COVID boosters may broaden immunity against animal coronaviruses

Clinical takeaway: When counseling older or medically vulnerable patients, clinicians can emphasize that COVID-19 boosters remain clinically relevant for reducing severe disease from circulating variants. This study also adds a forward-looking point: repeated vaccination may broaden immune readiness against some related coronaviruses with spillover potential.

COVID-19 vaccine boosters may do more than refresh protection against SARS-CoV-2. In a new study, researchers found that serum from older adults who had received four COVID-19 vaccine doses showed unexpectedly broad neutralizing activity against some SARS-CoV-2–related animal coronaviruses.

Older adults and immunocompromised patients are often at highest risk when new respiratory viruses emerge. The study does not show that current boosters would prevent a future coronavirus pandemic, but it suggests that repeated vaccination may help build broader immune protection that could reduce severity or transmission early in an outbreak, before a targeted vaccine is available.

Researchers evaluated blood samples from 22 older adults in the UK, with a median age of 68.5 years, about one month after a fourth COVID-19 vaccine dose. The fourth dose was a bivalent vaccine targeting the original Wuhan strain and Omicron BA.1. Investigators tested neutralizing antibody activity against several Omicron variants and against sarbecoviruses, the coronavirus group that includes SARS-CoV-1, SARS-CoV-2, and related bat and pangolin viruses.

As expected, neutralization was weaker against newer Omicron variants than against the original SARS-CoV-2 strain, consistent with immune escape and immune imprinting from earlier exposures. Neutralization was also poor against SARS-CoV-1 and a related bat virus, which are more genetically distant from SARS-CoV-2.

The more notable finding was that antibodies from vaccinated participants neutralized two SARS-CoV-2–related animal viruses especially well: BANAL-20-52, a bat sarbecovirus, and a pangolin coronavirus. Neutralizing titers against those viruses were higher than against the original SARS-CoV-2 strain in the study’s assay. Several tested bat and pangolin viruses can enter human cells in laboratory models, which is one reason they are monitored as potential spillover threats.

The findings also point toward next-generation vaccine goals. Vaccines that target conserved parts of the coronavirus spike protein could potentially provide broader protection across SARS-CoV-2 variants and related animal coronaviruses.

Clinicians can frame boosters as more than a short-term update against current variants: repeated vaccination may help mature and broaden antibody responses over time. That broader immunity could become important if a related coronavirus crosses from animals into humans.

“We may already have a head start when it comes to protecting against certain future outbreaks,” said Rebecca Morse, a joint first author from the Cambridge Institute of Therapeutic Immunology & Infectious Disease at the University of Cambridge. “Boosters could reduce both severity and spread if spillover were to occur, buying us vital time while we develop a more targeted vaccine.”

Source: West GE, et al. (2026 July 1) npj Vaccines. COVID-19 vaccination induces cross-neutralisation of sarbecoviruses related to SARS-CoV-2